Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing

Guideline Committee

doi:10.1136/bmj.m1565

Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing

Guideline Committee

Division of Immunology, Immunity to Infection and Respiratory Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Venous thromboembolic (VTE) disease is a continuing global health burden with serious mortality, morbidity, and health economic consequences.1 The one year case fatality rate of definite or probable VTE has been estimated at 23%.2 Approximately 1 to 2 of every 1000 adults in the worldwide population will be diagnosed with VTE annually, with higher incidence rates in those over 70 (2 to 7/1000) and over 80 (3 to 12/1000).13

Original language	English
Pages (from-to)	m1565
Journal	BMJ (Clinical Research Edition)
Volume	369
DOIs	https://doi.org/10.1136/bmj.m1565
Publication status	Published - 19 May 2020

Keywords

4-Hydroxycoumarins/therapeutic use
Adult
Aftercare/standards
Anticoagulants/therapeutic use
Antiphospholipid Syndrome/drug therapy
England/epidemiology
Factor Xa Inhibitors/therapeutic use
Fibrin Fibrinogen Degradation Products/analysis
Heparin, Low-Molecular-Weight/therapeutic use
Humans
Incidence
Indenes/therapeutic use
International Normalized Ratio/methods
Neoplasms/drug therapy
Pyrazoles/therapeutic use
Pyridones/therapeutic use
Risk Assessment
Rivaroxaban/therapeutic use
State Medicine/organization & administration
Systematic Reviews as Topic
Thrombophilia/blood
Vena Cava Filters/standards
Venous Thromboembolism/diagnosis
Vitamin K/antagonists & inhibitors

Access to Document

10.1136/bmj.m1565

Cite this

@article{1321c97d552c4272ab76acd7acdd6d7c,

title = "Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing",

abstract = "Venous thromboembolic (VTE) disease is a continuing global health burden with serious mortality, morbidity, and health economic consequences.1 The one year case fatality rate of definite or probable VTE has been estimated at 23%.2 Approximately 1 to 2 of every 1000 adults in the worldwide population will be diagnosed with VTE annually, with higher incidence rates in those over 70 (2 to 7/1000) and over 80 (3 to 12/1000).13",

keywords = "4-Hydroxycoumarins/therapeutic use, Adult, Aftercare/standards, Anticoagulants/therapeutic use, Antiphospholipid Syndrome/drug therapy, England/epidemiology, Factor Xa Inhibitors/therapeutic use, Fibrin Fibrinogen Degradation Products/analysis, Heparin, Low-Molecular-Weight/therapeutic use, Humans, Incidence, Indenes/therapeutic use, International Normalized Ratio/methods, Neoplasms/drug therapy, Pyrazoles/therapeutic use, Pyridones/therapeutic use, Risk Assessment, Rivaroxaban/therapeutic use, State Medicine/organization & administration, Systematic Reviews as Topic, Thrombophilia/blood, Vena Cava Filters/standards, Venous Thromboembolism/diagnosis, Vitamin K/antagonists & inhibitors",

author = "{Guideline Committee} and Terry McCormack and Harrisingh, {Marie C} and Daniel Horner and Susan Bewley",

year = "2020",

month = may,

day = "19",

doi = "10.1136/bmj.m1565",

language = "English",

volume = "369",

pages = "m1565",

journal = "BMJ (Clinical Research Edition)",

issn = "0959-8138",

publisher = "BMJ ",

}

TY - JOUR

T1 - Venous thromboembolism in adults

T2 - summary of updated NICE guidance on diagnosis, management, and thrombophilia testing

AU - Guideline Committee

AU - McCormack, Terry

AU - Harrisingh, Marie C

AU - Horner, Daniel

AU - Bewley, Susan

PY - 2020/5/19

Y1 - 2020/5/19

N2 - Venous thromboembolic (VTE) disease is a continuing global health burden with serious mortality, morbidity, and health economic consequences.1 The one year case fatality rate of definite or probable VTE has been estimated at 23%.2 Approximately 1 to 2 of every 1000 adults in the worldwide population will be diagnosed with VTE annually, with higher incidence rates in those over 70 (2 to 7/1000) and over 80 (3 to 12/1000).13

AB - Venous thromboembolic (VTE) disease is a continuing global health burden with serious mortality, morbidity, and health economic consequences.1 The one year case fatality rate of definite or probable VTE has been estimated at 23%.2 Approximately 1 to 2 of every 1000 adults in the worldwide population will be diagnosed with VTE annually, with higher incidence rates in those over 70 (2 to 7/1000) and over 80 (3 to 12/1000).13

KW - 4-Hydroxycoumarins/therapeutic use

KW - Adult

KW - Aftercare/standards

KW - Anticoagulants/therapeutic use

KW - Antiphospholipid Syndrome/drug therapy

KW - England/epidemiology

KW - Factor Xa Inhibitors/therapeutic use

KW - Fibrin Fibrinogen Degradation Products/analysis

KW - Heparin, Low-Molecular-Weight/therapeutic use

KW - Humans

KW - Incidence

KW - Indenes/therapeutic use

KW - International Normalized Ratio/methods

KW - Neoplasms/drug therapy

KW - Pyrazoles/therapeutic use

KW - Pyridones/therapeutic use

KW - Risk Assessment

KW - Rivaroxaban/therapeutic use

KW - State Medicine/organization & administration

KW - Systematic Reviews as Topic

KW - Thrombophilia/blood

KW - Vena Cava Filters/standards

KW - Venous Thromboembolism/diagnosis

KW - Vitamin K/antagonists & inhibitors

U2 - 10.1136/bmj.m1565

DO - 10.1136/bmj.m1565

M3 - Article

C2 - 32430311

SN - 0959-8138

VL - 369

SP - m1565

JO - BMJ (Clinical Research Edition)

JF - BMJ (Clinical Research Edition)

ER -

Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing

Abstract

Keywords

Access to Document

Fingerprint

Cite this